摘要
探讨NF-κB1基因rs3774937、rs3774959、rs3774963位点基因多态性与急性白血病患者异基因造血干细胞移植(Allo-HSCT)后并发急性肾损伤(AKI)的相关性。选取2018年1月至2021年12月于江苏省人民医院接受Allo-HSCT的急性白血病患者82例,应用TaqMan探针法检测NF-κB1基因rs3774937、rs3774959、rs3774963位点基因型。与非AKI组相比,AKI患者rs3774937位点CC基因型和C等位基因频率、rs3774959位点AA基因型和A等位基因频率、rs3774963位点GG基因型和G等位基因频率均明显增高(P<0.05)。回归分析显示,rs3774937位点CC基因型、rs3774959位点AA基因型、rs3774963位点GG基因型与AKI发生风险增加相关(P<0.05),并且血肌酐水平较其他基因型更高(P<0.05)。单倍体分析显示,C-A-G单倍体携带者与AKI发生风险增加相关(P<0.05)。本研究结果提示,NF-κB1基因rs3774937、rs3774959和rs3774963位点可能作为Allo-HSCT术后并发AKI的易感遗传标记。
The aim of the authors′ present study was to investigate the association of three single nucleotide polymorphisms sites, including rs3774937,rs3774959,and rs3774963,in NF-κB1 gene with the risk of acute kidney injury(AKI) in acute leukemia patients receiving allogeneic hematopoietic stem cell transplantation(Allo-HSCT).A total of 82 patients with acute leukemia who received Allo-HSCT in Jiangsu Province Hospital from January 2018 to December 2021 were enrolled.The genotypes of rs3774937,rs3774959,and rs3774963 in NF-κB1 gene were examined by TaqMan technology.The results showed that the frequencies of CC genotype at rs3774937,AA genotype at rs3774959,and GG genotype at rs3774963 were increased in patients with AKI(P<0.05).Similar results were observed in the frequencies of C allele, A allele, and G allele in patients with AKI at the polymorphism sites of rs3774937,rs3774959,and rs3774963,respectively(P<0.05).Multiple logistical regression analysis showed that patients with these three genotypes had higher risk of AKI as well as high levels of serum creatine when compared to those with other genotypes(P<0.05).Further haplotype-based analysis revealed that individuals with C-A-G haplotype had higher risk of AKI than those with other haplotypes(P<0.05).Taken together, the results of the authors′ present study suggests that the polymorphisms of NF-κB1 might be served as potential genetic markers for the instance of AKI in patients receiving Allo-HSCT.
作者
闫薛
缪扣荣
YAN Xue;MIAO Kou-rong(Hematology Department of Jiangning Hospital,Nanjing Medical University,Nanjing 211199,China;Department of Hematology,the First Afiliated Hospital of Nanjing Medical University,Nanjing 211100,China)
出处
《药物生物技术》
CAS
2023年第1期7-11,共5页
Pharmaceutical Biotechnology
基金
国家自然科学基金(No.81470329)。